A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

Inclusion Criteria:

• Participant must be 18 to 85 years of age inclusive.

• Clinical history consistent with NCFB (cough, chronic sputum production and/orrecurrent respiratory infections).

• Participants with a FEV1 % predicted ≥30%.

• Participants with at least 2 moderate or 1 severe Pulmonary exacerbations (PEs) inthe past 12 months.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Have bronchiectasis due to CF, hypogammaglobulinemia, common variableimmunodeficiency, known active nontuberculous mycobacteria (NTM) lung infection, orpulmonary fibrosis.

• Known or suspected immunodeficiency disorder.

• Pulmonary exacerbation which has not resolved clinically during screening period.

• Have significant haemoptysis.

• Have any clinically significant abnormal laboratory values at Screening or diseasesor disorders.

• History of lung transplantation.

• History of malignancy within 5 years before Screening, or during the screeningperiod

• Currently being treated with antimicrobial therapy for tuberculosis (TB).

• Currently on active treatment for allergic bronchopulmonary aspergillosis (ABPA).

• Participants with active autoimmune disease or participants using immunosuppressivetherapy for autoimmune disease

• Known allergy to itepekimab or to excipients

• Live-attenuated vaccine(s) within 4 weeks prior to Screening or plans to receivesuch vaccines during the study

• Unstable ischemic heart disease

• Cardiomyopathy or other relevant cardiovascular disorder

• Clinically significant new abnormal electrocardiogram (ECG) within 6 months priorto, or at Screening

• History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serologyat Screening.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.